FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380079062> ?p ?o ?g. }

• W4380079062 endingPage "711" @default.
• W4380079062 startingPage "711" @default.
• W4380079062 abstract "Introduction: Diffuse large B-cell lymphoma (DLBCL) is an aggressive, potentially curable cancer. Although a standard regimen R-CHOP has been shown to cure majority of elderly DLBCL patients. However, some elderly patients can’t tolerate the full-dose of R-CHOP due to age, poor physical condition, and severe comorbidities. The Italian Lymphoma Foundation has showed that comprehensive geriatric assessment (CGA) in elderly DLBCL patients can help to objectively and accurately identify patients who were fit for the full-dose of R-CHOP regimens. This multicenter, prospective, observational, controlled cohort study aims to investigate the effectiveness and safety of comprehensive geriatric assessment (CGA) to guide the treatment in elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in China. Methods: 155 patients from 4 centers in Beijing were enrolled between February 1st 2016 and February 1st2021(ChiCTR1800016732). Physicians with the same level of academic title in each center were divided into two groups: experimental group and controlled group. In the experimental group, physicians were required to decide treatment based on the results of CGA. In the control group, physicians were blind to CGA results and decided the treatment based on their own clinical experience. 78 patients in the experimental group who will received CGA-driven therapy, 77 patients in the controlled group will received therapy based on clinical judgement. The primary endpoint was 3-year Progression Free Survival (PFS) between two group, the secondary endpoint were Objective Response Rate (ORR), 3-year Overall Survival (OS), or treatment-related adverse events between two groups. Results: the baseline clinical characteristics of two groups were comparable. According to CGA, 78 patients in the experimental group were classified into three groups: fit (41 patients, 52.6%), unfit (4 patients, 5.1%) and frail group (33 patients, 42.3%). the ORR was 94.9% (74/78), including CR rate was 70.5% (55/78). 3-year OS rates was 79.2%, 3-year PFS rates was 72.9%. however, in the controlled group, the ORR was 81% (62/77), including CR rate was 52% (40/77). 3-year OS rates was 66.2%, 3-year PFS was 54.5%. there was significant difference between the two groups (ORR: x2 = 7.421, p = 0.006; CR: x2 = 5.629, p = 0.018; 3-year PFS rates: x2 = 5.5, p = 0.019). the toxicity between two group was similar. the number of patients who had lymphoma progression or relapse in the controlled group was higher than that in the experimental group (45.5% vs. 23.4%, p < 0.05). lymphoma progression rather than toxicity was the main cause of death among controlled group. Keywords: aggressive B-cell non-Hodgkin lymphoma, Therapeutics and Clinical Trials in Lymphoma - Other No conflicts of interests pertinent to the abstract." @default.
• W4380079062 created "2023-06-10" @default.
• W4380079062 creator A5009247999 @default.
• W4380079062 creator A5018006177 @default.
• W4380079062 creator A5036032938 @default.
• W4380079062 creator A5040271009 @default.
• W4380079062 creator A5048678875 @default.
• W4380079062 creator A5053693489 @default.
• W4380079062 creator A5078242086 @default.
• W4380079062 creator A5080351759 @default.
• W4380079062 creator A5089148555 @default.
• W4380079062 date "2023-06-01" @default.
• W4380079062 modified "2023-10-12" @default.
• W4380079062 title "CGA‐DRIVEN THERAPEUTIC DECISION IN ELDERLY PATIENTS WITH PREVIOUSLY UNTREATED DLBCL IN CHINA: A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, CONTROLLED COHORT STUDY" @default.
• W4380079062 doi "https://doi.org/10.1002/hon.3165_565" @default.
• W4380079062 hasPublicationYear "2023" @default.
• W4380079062 type Work @default.
• W4380079062 citedByCount "0" @default.
• W4380079062 crossrefType "journal-article" @default.
• W4380079062 hasAuthorship W4380079062A5009247999 @default.
• W4380079062 hasAuthorship W4380079062A5018006177 @default.
• W4380079062 hasAuthorship W4380079062A5036032938 @default.
• W4380079062 hasAuthorship W4380079062A5040271009 @default.
• W4380079062 hasAuthorship W4380079062A5048678875 @default.
• W4380079062 hasAuthorship W4380079062A5053693489 @default.
• W4380079062 hasAuthorship W4380079062A5078242086 @default.
• W4380079062 hasAuthorship W4380079062A5080351759 @default.
• W4380079062 hasAuthorship W4380079062A5089148555 @default.
• W4380079062 hasBestOaLocation W43800790621 @default.
• W4380079062 hasConcept C121608353 @default.
• W4380079062 hasConcept C126322002 @default.
• W4380079062 hasConcept C143998085 @default.
• W4380079062 hasConcept C188816634 @default.
• W4380079062 hasConcept C197934379 @default.
• W4380079062 hasConcept C203092338 @default.
• W4380079062 hasConcept C23131810 @default.
• W4380079062 hasConcept C2777319248 @default.
• W4380079062 hasConcept C2778476033 @default.
• W4380079062 hasConcept C2778559949 @default.
• W4380079062 hasConcept C2779338263 @default.
• W4380079062 hasConcept C2781413609 @default.
• W4380079062 hasConcept C535046627 @default.
• W4380079062 hasConcept C61943457 @default.
• W4380079062 hasConcept C71924100 @default.
• W4380079062 hasConcept C72563966 @default.
• W4380079062 hasConceptScore W4380079062C121608353 @default.
• W4380079062 hasConceptScore W4380079062C126322002 @default.
• W4380079062 hasConceptScore W4380079062C143998085 @default.
• W4380079062 hasConceptScore W4380079062C188816634 @default.
• W4380079062 hasConceptScore W4380079062C197934379 @default.
• W4380079062 hasConceptScore W4380079062C203092338 @default.
• W4380079062 hasConceptScore W4380079062C23131810 @default.
• W4380079062 hasConceptScore W4380079062C2777319248 @default.
• W4380079062 hasConceptScore W4380079062C2778476033 @default.
• W4380079062 hasConceptScore W4380079062C2778559949 @default.
• W4380079062 hasConceptScore W4380079062C2779338263 @default.
• W4380079062 hasConceptScore W4380079062C2781413609 @default.
• W4380079062 hasConceptScore W4380079062C535046627 @default.
• W4380079062 hasConceptScore W4380079062C61943457 @default.
• W4380079062 hasConceptScore W4380079062C71924100 @default.
• W4380079062 hasConceptScore W4380079062C72563966 @default.
• W4380079062 hasIssue "S2" @default.
• W4380079062 hasLocation W43800790621 @default.
• W4380079062 hasOpenAccess W4380079062 @default.
• W4380079062 hasPrimaryLocation W43800790621 @default.
• W4380079062 hasRelatedWork W2115179216 @default.
• W4380079062 hasRelatedWork W2317141594 @default.
• W4380079062 hasRelatedWork W2329713498 @default.
• W4380079062 hasRelatedWork W2397442087 @default.
• W4380079062 hasRelatedWork W2510018373 @default.
• W4380079062 hasRelatedWork W2922282492 @default.
• W4380079062 hasRelatedWork W2979656752 @default.
• W4380079062 hasRelatedWork W3217255858 @default.
• W4380079062 hasRelatedWork W4232815876 @default.
• W4380079062 hasRelatedWork W4320012106 @default.
• W4380079062 hasVolume "41" @default.
• W4380079062 isParatext "false" @default.
• W4380079062 isRetracted "false" @default.
• W4380079062 workType "article" @default.